152 related articles for article (PubMed ID: 34887522)
1. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Konstantinopoulos PA; Cheng SC; Supko JG; Polak M; Wahner-Hendrickson AE; Ivy SP; Bowes B; Sawyer H; Basada P; Hayes M; Curtis J; Horowitz N; Wright AA; Campos SM; Ivanova EV; Paweletz CP; Palakurthi S; Liu JF; D'Andrea AD; Gokhale PC; Chowdhury D; Matulonis UA; Shapiro GI
Br J Cancer; 2022 Apr; 126(7):1027-1036. PubMed ID: 34887522
[TBL] [Abstract][Full Text] [Related]
2. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
[TBL] [Abstract][Full Text] [Related]
3. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status.
Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R
J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344
[TBL] [Abstract][Full Text] [Related]
4. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
Ghosh M; Kang MS; Katuwal NB; Hong SD; Jeong YG; Park SM; Kim SG; Moon YW
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069409
[TBL] [Abstract][Full Text] [Related]
5. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Wethington SL; Shah PD; Martin L; Tanyi JL; Latif N; Morgan M; Torigian DA; Rodriguez D; Smith SA; Dean E; Domchek SM; Drapkin R; Shih IM; Brown EJ; Hwang WT; Armstrong DK; Gaillard S; Giuntoli R; Simpkins F
Clin Cancer Res; 2023 Aug; 29(15):2800-2807. PubMed ID: 37097611
[TBL] [Abstract][Full Text] [Related]
6. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V; Wang AT; Castroviejo-Bermejo M; Polanska UM; Palafox M; Herencia-Ropero A; Jones GN; Lai Z; Armenia J; Michopoulos F; Llop-Guevara A; Brough R; Gulati A; Pettitt SJ; Bulusu KC; Nikkilä J; Wilson Z; Hughes A; Wijnhoven PWG; Ahmed A; Bruna A; Gris-Oliver A; Guzman M; Rodríguez O; Grueso J; Arribas J; Cortés J; Saura C; Lau A; Critchlow S; Dougherty B; Caldas C; Mills GB; Barrett JC; Forment JV; Cadogan E; Lord CJ; Cruz C; Balmaña J; O'Connor MJ
Clin Cancer Res; 2022 Oct; 28(20):4536-4550. PubMed ID: 35921524
[TBL] [Abstract][Full Text] [Related]
9. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
10. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
11. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045.
Kim YN; Joung JG; Park E; Kim JW; Lee JB; Lim J; Kim S; Choi CH; Kim HS; Chung J; Kim BG; Lee JY
Int J Cancer; 2023 Dec; 153(12):2032-2044. PubMed ID: 37602928
[TBL] [Abstract][Full Text] [Related]
12. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
13. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
14. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
15. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
16. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
17. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106
[TBL] [Abstract][Full Text] [Related]
18. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
19. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
[TBL] [Abstract][Full Text] [Related]
20. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
